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ARTICLELoss of Dermatan-4-Sulfotransferase 1 Function
Results in Adducted Thumb-Clubfoot Syndrome
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Lijuan Zhang,3 and Andreas R. Janecke2,8,*
Adducted thumb-clubfoot syndrome is an autosomal-recessive disorder characterized by typical facial appearance, wasted build, thin
and translucent skin, congenital contractures of thumbs and feet, joint instability, facial clefting, and coagulopathy, as well as heart,
kidney, or intestinal defects. We elucidated the molecular basis of the disease by using a SNP array-based genome-wide linkage approach
that identiﬁed distinct homozygous nonsense and missense mutations in CHST14 in each of four consanguineous families with this
disease. The CHST14 gene encodes N-acetylgalactosamine 4-O-sulfotransferase 1 (D4ST1), which catalyzes 4-O sulfation of N-acetylga-
lactosamine in the repeating iduronic acid-a1,3-N-acetylgalactosamine disaccharide sequence to form dermatan sulfate. Mass spectrom-
etry of glycosaminoglycans from a patient’s ﬁbroblasts revealed absence of dermatan sulfate and excess of chondroitin sulfate, showing
that 4-O sulfation by CHST14 is essential for dermatan sulfate formation in vivo. Our results indicate that adducted thumb-clubfoot
syndrome is a disorder resulting from a defect speciﬁc to dermatan sulfate biosynthesis and emphasize roles for dermatan sulfate in
human development and extracellular-matrix maintenance.Introduction
Glycosaminoglycans such as dermatan sulfate (DS), chon-
droitin sulfate (CS), and heparan sulfate (HS) are long
chains of repeating disaccharide subunits that are cova-
lently bound to serine residues of a variety of core proteins
via an O-linked tetrasaccharide linkage sequence O-xylose-
galactose-galactose-glucuronic acid to form proteoglycans
as shown schematically in Figure 1.1 Addition of a b-N-ace-
tylgalactosamine (GalNAc) to the linkage sequence by
GalNAc transferase I (MIM 602273) distinguishes CS and
DS from HS. The CS C-5 hydroxyl of glucuronic acid
(GlcUA) is epimerized to iduronic acid (IdoUA) by glucur-
onyl C5-epimerases.2 The addition of sulfate to the C-4
hydroxyl of GalNAc prevents further epimerization of the
adjacent GlcUA or IdoUA. Four GalNAc-4-sulfotransferases
have been described that differentiate between CS and DS
chondroitin 4-sulfotransferases 1–3 (CHST11 [MIM
610128], CHST12 [MIM 610129], CHST13 [MIM 610124])
and dermatan-4-O-sulfotransferase 1 (CHST14 (D4ST1)
[MIM 608429]).3,4 CHST12 has been reported to transfer
sulfate to both chondroitin and dermatan;5 however, it
does not demonstrate a marked preference for chondroitin
or dermatan and requires high concentrations of acceptor
to obtain signiﬁcant levels of sulfate transfer. Dermatan
sulfate can be further modiﬁed by the addition of sulfate
to the C-2 hydroxyl of the IdoA and, to a lesser extent, of
the GlcA, as well as to the C-4 or C-6 hydroxyls of terminalGalNAc.6 In each case 30-phosphoadenosine 50-phospho-
sulfate acts as the sulfate donor, and transfer occurs in
the trans network of the Golgi. The proportion of IdoUA
and GlcUA and the degree of sulfation in DS vary consider-
ably in tissues and, in the case of cultured cells, are inﬂu-
enced by the level of free sulfate in the culture medium.7
Mature proteoglycans have been implicated in a wide
range of biological processes, including cell migration,
proliferation, and survival, as well as modulation of
growth-factor signaling. Although the roles of HS and CS
in development and growth-factor signaling have been
extensively studied,8–11 the biological function of DS is
less well understood.12,13 DS proteoglycans have wide-
spread distribution in mammalian tissues, such as blood
vessel walls, skin, tendon, sclera, cartilage, and in undiffer-
entiated mesenchymal tissue,14 where they participate in
extracellular matrix (ECM) organization, neurite out-
growth, wound repair, anticoagulant processes, and cell
adhesion, migration, and proliferation.15,16 DS proteogly-
cans include decorin, biglycan, versican, and endocan.15
Interactions between DS proteoglycans and particular
target molecules have been described for their core
proteins as well as their DS chains. The biological activities
of DS have been attributed to its content of C-4 sulfated
IdoUA-GalNAc disaccharide units.12,17
In this study, we identiﬁed four distinct homozygous
mutations in CHST14 in patients with the adducted
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four families. We recently delineated ATCS as an auto-
somal-recessive, generalized connective tissue disorder
with congenital, distal contractures, a variable degree of
congenital malformations, and normal cognitive develop-
ment.18–20 The identiﬁed CHST14 mutations abolish or
decrease D4ST1 activity by early protein truncation and
altered intracellular protein processing, resulting in a
decrease of DS and increase of CS in patient ﬁbroblasts
and in the culture medium. To the best of our knowledge,
ATCS appears to be the ﬁrst disorder caused by a defect
speciﬁc to DS biosynthesis, producing a generalized
involvement of organs and revealing roles for DS in human
development and ECM maintenance.
Material and Methods
Subjects
Eleven patients with ATCS from four consanguineous families of
Austrian (family 1), Turkish (families 2 and 3), and Japanese (family
4) descent were identiﬁed in the course of this study. Initial clinical
descriptions of seven patients from these four families have been
published.18–21 The patients from family 4were originally reported
as representing ‘‘a new type of distal arthrogryposis.’’21 ATCS repre-
sents a generalized connective tissue disorder with normal cogni-
tive development. ATCS can be recognized clinically by a pattern
of symptoms comprising a severelywasted build and dry and trans-
lucentskin,brachycephaly,andfacialcharacteristics suchasabroad
and ﬂat forehead, hypertelorism, downward-slanting palpebral
ﬁssures,malar ﬂatness, retrognathia, andprominent ears (Figure 2).
The anterior fontanel is large at birth, and closure is delayed until
after 2 years of age. Congenital contractures of the thumbs improve
spontaneously within weeks, whereas congenital clubfeet require
surgical treatment. Marked arachnodactyly and tapering of the
ﬁngers, as well as hypermobility of the small joints of the hands,
feet, and the shoulders, are present.Delayedwoundhealing, ecchy-
moses, and hematoma formation were recorded. Detailed analyses
of bloodcoagulation inan8-year-oldpatient fromfamily1 revealed
a prolonged bleeding time (9 min, reference range: < 7 min), indi-
cating the presence of a coagulopathy in addition to a form of
generalized connective tissue weakness. Mild osteopenia is
apparent in childhood (Figure 3); however, bone densitometry of
the lumbar spine was normal in the 8-year-old proband of the Aus-
trian familybut revealedosteopenia (Z score1.6) andosteoporosis
(Z score 4.6) in the two Turkish siblings at age 15 and 6 years,
respectively, all three of whose photographs are shown in Figure 2.
Minordegreesof cranial ventricular enlargementwerepresent inall
ﬁve patients examined. Bluish sclerae and intermittent exotropia
were observed in four patients. An atrial septal heart defect was
noted in two patients and mild coarctation of the aorta in one
patient. One patient was found to have a horseshoe kidney, and
two patients had bilateral hydronephrosis. All examined male
patients were found to have undescended testes at birth. A cleft
palate and cleft lip and palate were present in sibs from a Japanese
family. Absence of the gastrocolic omentum was observed in
association with a spontaneous volvulus of the small intestine in
one Austrian ATCS patient, and a commonmesentery was present
in his deceased brother. This patient was born at 31 weeks of gesta-
tion with heart and kidney defects and died at birth from respira-
tory failure. Three affected children from two Turkish families
died before four months of age and one child at age six years, and
the causes of death were not recorded.
Linkage and Mutation Analysis
Written informed consent for molecular studies was obtained
from all participants, and the study was conducted in accordance
with the principles of the declaration of Helsinki. We carried out a
genome-wide linkage scan with the Affymetrix XbaI 50K SNP
arrays in four affected and 11 unaffected individuals from families
1–3 with ATCS (Figure 4). Parametric multipoint LOD score calcu-
lations and haplotypes were obtained with the ALLEGRO
program22 and an autosomal-recessive, fully penetrant model.
We selected two genes from the candidate region (THBS1 [MIM
188060],CHST14) on the basis of known functions and expression
patterns for mutation analysis. Primer sequences were based on
the National Center for Biotechnology Information (NCBI) refer-
ence entries for mRNA and genomic DNA of each gene (CHST14,
Figure 1. Biosynthesis of Dermatan Sulfate
and Chondroitin Sulfate
Chondroitin sulfate (CS), dermatan sulfate
(DS), and also heparin sulfate share the
synthesis of a tetrasaccharide linker region
that attaches the glycosaminoglycan chains
to a serine within the conserved attachment
site of core proteins. The activity of a unique
N-acetylgalactosaminyltransferase (GalNAcT-I)
that transfers the ﬁrst residue onto the tetra-
saccharide linker starts a growing glycosami-
noglycan chain to CS. This step is followed
by the activities of speciﬁc enzymes that
polymerize the glycosaminoglycan chain by
the alternating addition of N-acetylgalactos-
amine (GalNAc) and glucoronic acid (GlcUA)
moieties in CS. CS chains can be modiﬁed
during elongation by a Golgi resident epim-
erase and a number of sulfotransferases.
Epimerization of GlcUA to iduronic acid
(IdoUA) by 5-hydroxyl epimerase (CS/DS5
epi) followed by sulfate addition to the C4
hydroxyl of the adjacent GalNAc residue by
D4ST1 generates DS from CS and prevents
back-epimerization of IdoUA to GlcUA.874 The American Journal of Human Genetics 85, 873–882, December 11, 2009
Figure 2. Clinical Features of ATCS
Left column: Austrian patient from family 1, homozygous for CHST14mutation p.R213P at age 8 years; clinical ﬁndings were previously
reported as case 2 by Janecke et al.20
Middle column: Turkish patient from family 3, homozygous for p.V49X at age 15 years; clinical ﬁndings were previously reported as case
2 by Dundar et al.18
Right column: 6-year-old sister of previous patient. Note the wasted build with weights below the 3rd centile and heights between the
25th to 50th centiles in all patients. The skin is translucent with readily visible venous pattern over the chest, abdomen, and extremities.
Note long and tapering ﬁngers, excessively wrinkled palms, and clubfeet (repaired in the Austrian patient).NM_130468.2 and AC013356; THBS1, NM_003246.2 and
AC037198) and are available from the authors. The coding regions
and splice sites were PCR ampliﬁed and directly sequenced in one
patient from each family. The sequencing reactions were analyzed
on an ABI 3100 DNA sequencer, with BigDye terminator mix
(Applied Biosystems, Vienna, Austria). Relatives were tested for
mutations detected in a proband. A panel of 300 Austrian, 200
Turkish, and 50 Japanese DNA samples from anonymous controls
was analyzed for the presence of each sequence variation.
Electron Microscopy
Skin specimens (2 3 2 mm) were ﬁxed in 0.1 M cacodylate buffer
pH 7.0 containing 3% of freshly prepared glutaraldehyde on ice
for 4 hr. Then the specimens were thoroughly washed with the
same buffer but without the glutaraldehyde and further processed
for routine electron microscopy (EM).
Analysis of Epitope-Tagged D4ST1
Wild-type D4ST1, p.R213P, p.[R135G; L137Q], and p.Y293C were
ligated into pcDNA3.1/V5 (Invitrogen) in frame with the carboxy-
terminal epitope tag V5, and p.V49X was ligated into pcDNA3.1/
V5 in frame with the aminoterminal tag V5, and they were
expressed in HEK293/T cells. Cells were washed and extracted
with T-PER tissue protein extraction reagent (Pierce) containing
Complete Protease Inhibitor that was EDTA free (CPI-EDTA free)The American(RocheMolecular Biochemicals). Digestions with Endoglycosidase
H (Boehringer Mannheim) and N-Glycanase (NEB) were per-
formed as described.23 Equivalent amounts of cell extracts and
media were analyzed by SDS-PAGE with 10% NuPage Bis-Tris
MOPS polyacrylamide gels (Invitrogen). After electrophoretic
transfer to PVDF membranes (Millipore), epitope-tagged proteins
were detected with HRP-antiV5 (Invitrogen).
Analysis of Glycosaminoglycans from Patient
and Normal Fibroblasts
Metabolic incorporation of 34S-sulfate in the available ﬁbroblasts
from a patient homozygous for p.R213P and in the ﬁbroblasts
from a normal control was conducted in 50%Dulbecco’s modiﬁed
Eagle’s medium (DMEM) and 50%Ham’s F-12medium containing
10% dialyzed fetal bovine serum and 1 mM 34S-sulfate. After
5 days in culture, the media were collected and replaced with fresh
media containing 1 mM 34S-sulfate. At day 9, media and cells were
collected separately. After the homogenizing of cells with a Poly-
tron, proteins in the media and homogenized cells were digested
with Streptomyces Griseus protease (Sigma P5147), and the
released glycosaminoglycans were isolated by chromatography
on DEAE-Sephacel as described. Glycosaminoglycans were freed
of core peptide by b-elimination followed by DEAE-Sephacel puri-
ﬁcation. Disaccharides for analysis were produced by digestion of
glycosaminoglycans with chondroitinase ACII (EC 4.2.2.5),Journal of Human Genetics 85, 873–882, December 11, 2009 875
chondroitinase B, or chondroitinase ABC (EC 4.2.2.4) purchased
from Seikagaku. All three chondroitinases produce unsaturated
uronic acid (DUA)-containing disaccharides. Chondroitinase
ACII degrades CS, chondroitinase B degrades DS, and chondroiti-
nase ABC degrades both CS and DS.
The reducing ends of the chondroitinase digestion products
were labeled with H-aniline (normal) or D5-aniline (patient) by
reductive amination as described.24 Separations were performed
on a 0.3 3 250 mm C18 column (Zorbax 300SB, 5 mm, Agilent)
with an Agilent 1100 series capillary HPLC workstation (Agilent)
with Chemstation software for data acquisition, analysis, and
management. The capillary high-performance liquid chromatog-
raphy (HPLC) was directly coupled to the mass spectrometer.
Mass spectra were acquired on a Mariner BioSpectrometry Work-
station ESI time-of-ﬂight mass spectrometer (PerSeptive Biosys-
tems) in the negative-ion mode. Total ion current chromatograms
and mass spectra were processed with Data Explorer software
version 3.0. The disaccharides from patient and NORMAL ﬁbro-
blasts were separately labeled with the glycan reductive isotope
labels25 (GRIL) normal aniline (H-analine) and deuterated analine
(D-analine), allowing simultaneous comparison of GRIL-tagged
glycosaminoglycans from two sources and eliminating variation
associated with capillary HPLC-coupled MS analysis.
Results
Identiﬁcation of N-Acetylgalactosamine
4-O-Sulfotransferase Gene Mutations
A genome-wide linkage scan in three families with ATCS
identiﬁed a single candidate region of 3.76Mb on chromo-
Figure 3. Radiographs Showing Generalized, Mild to Moderate
Osteopenia in All Examined ATCS Patients
(A) Flat foot with plantar ﬂexion of the talus. Rareﬁcation of bone
with reduced and coarse trabeculation, as well as thinning of the
cortex, is shown.
(B–F) Slender shafts of tubular bones with thin cortex and poorly
trabeculated spongiosa.
(A) and (B) show Austrian patient (family 1) homozygous for
p.R213P at age 8 years; (C) and (D) show Turkish patient (family
3) homozygous for p.V49X at age 15 years; (E) and (F) show
6-year-old sister of previous patient).876 The American Journal of Human Genetics 85, 873–882, Decembsome 15q15 (multipoint LOD score of Z ¼ 5.91 [q ¼ 0.0] at
several SNPs within this interval, Figure 4A). The bound-
aries were set between SNPs rs10520118 and rs10518779
by two recombinants. We identiﬁed 73 genes in this crit-
ical region in the annotated draft sequence of the human
genome (NCBI map, Build 36.2), including THBS1 encod-
ing for thrombospondin and CHST14 encoding for
D4ST1, which we considered as plausible candidates.
Thrombospondin is known to be involved in TGFB
signaling,26 and D4ST1 is known to play a role in themodi-
ﬁcation of ECM proteins.3 Direct sequencing revealed no
mutations in THBS1. However, we identiﬁed a 1 bp dele-
tion (c.145_146 delG resulting in p.V49X), a missense
mutation (c.638G>C; p.R213P), and a complex allele
c.[404C>G; 410T>A] (p.[R135G; L137Q]) in CHST14 in
the three original ATCS families (Figure 4B, families 1–3)
from Austria and from Turkey.18–20 We also identiﬁed a
homozygous point mutation (c.878A>G; p.Y293C) in a
consanguineous family from Japan subsequently identi-
ﬁed with the clinical features of ATCS (family 4, Figure 4).21
We showed that six informative microsatellite markers
spanning a 15 cM interval around CHST14 are homozy-
gous in both Japanese patients from this family, providing
evidence for the pathogenicity of this mutation. In each
case, the mutation segregated with disease status in the
family and was not present in control samples.
The single CHST14 exon encodes a type II membrane
protein of 376 amino acids belonging to the family of
HNK-1 sulfotransferases with a 43 amino acid cytoplasmic
domain and a 316 amino acid luminal domain. A single
2.4 kb transcript is ubiquitously but most highly expressed
in connective tissues, heart, liver, pancreas, and placenta.3
Each of the identiﬁed mutations has the potential to alter
D4ST1 activity and cause disease. The p.V49X mutation
leads to early protein truncation. Arg-213, which is known
to mediate hydrogen bonding to 30-phosphoadenosine
50-phosphosulfate, and Tyr-293 are highly conserved
amongmembers from theHNK1 family as well as a number
of other carbohydrate sulfotransferase families. Residues
Arg-135 and Leu-137 are present in a 4 amino acid
sequence that is speciﬁc to D4ST1 among the HNK-1 sulfo-
transferases and is conserved among D4ST1 orthologs
(Figure 5A). An analysis using the in silico tools PolyPhen
and PANTHER predicted damaging effects of the identiﬁed
missense mutations on protein function (Table 1).
Normal Structure and Ultrastructure
of a Patient’s Skin Biopsy
Light and electron microscopy revealed no alterations in a
biopsy from a patient (family 1) homozygous for the
D4ST1 mutation p.R213P (Figure 6).
Altered Intracellular Processing
of D4ST1 Missense Mutations
Immunoblotting of recombinant D4ST1 revealed wild-
type migrating as a major species with a Mr of 55 kD and
less prominent species with a Mr of 44 kD that arises byer 11, 2009
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Figure 4. Pedigrees and Linkage and Mutation Analyses of ATCS Families
(A) The graph represents a parametric LOD score on the y axis in relation to genetic position on the x axis. Human chromosomes are
concatenated from p-ter (left) to q-ter (right) on the x axis, and the genetic distance is given in cM. This scan identiﬁed a single region
of extended homozygosity shared by all four affected individuals included in the genome scan, who are identiﬁed in (B), deﬁning a
critical interval of 3.76 Mb on chromosome 15q15.
(B) The pedigrees of the four ATCS families included in this study are shown and the corresponding CHST14mutations are shown on the
right-hand side. A total of 15 subjects from families 1–3, identiﬁed by the & symbol, were included in the genome scan to map the
disease. Family 1 originates from Austria and clinical ﬁndings were initially reported in 2001.20 The Turkish families 2 and 3 were ﬁrst
reported in 200119 and 1997,18 and detailed clinical ﬁndings of family 4 from Japan were reported in 2000.21proteolytic cleavage in the region between the transmem-
brane domain and the glycosylated asparagine located at
position 110 (Figure 5B). Only trace amounts of the 55 kD
species are seen in cells expressing either p.R213P or
p.[R135G; L137Q]; instead, the 44 kD form predominates.
No product is detected for p.V49X, whereas the 55 kD
species predominates in p.Y293-expressing cells. Wild-
type D4ST1, p.R213P, p.Y293C, and p.[R135G; L137Q]
are sensitive to digestion to both endoglycosidase H (not
shown) and N-glycanase, indicating that oligomannose-
type oligosaccharides are present. The intracellular pro-
cessing of p.R213P and p.[R135G; L137Q] is distinct from
that of wild-type D4ST1 with only trace amounts of the
membrane-anchored form remaining. Wild-type D4ST1
is found in the medium of transfected 293T cells, whereas
D4ST1 is not found in signiﬁcant quantities in themedium
of cells transfected with D4ST1 containing any of the
missense mutations (Figure 5B, lower panel). The absence
of the missense mutants in the medium suggests that the
intracellular processing of each of these forms differs
from that of wild-type and that they may not reach the
Golgi but instead be degraded.The AmericanDecreased DS Biosynthesis and Increased CS Content
in Patient-Derived Fibroblasts
We addressed the impact of the p.R213P mutation by
comparing DS biosynthesis by cultured ﬁbroblasts from
a patient homozygous for p.R213P with normal controls.
Stable isotope-labeled glycosaminoglycans obtained from
the cell pellet and the medium were exhaustively digested
with chondroitinase AC, B, or ABC to generate DUA-con-
taining disaccharides from CS, DS, and both CS and DS,
respectively. DS-derived IdoUA-GalNAc432S (m/z535) is
present in cell- and media-associated glycosaminoglycans
from normal ﬁbroblasts and can be biosynthetically
labeled with 34S-sulfate to form IdoUA-GalNAc434S (m/z
537). No DS-derived IdoUA-GalNAc4S disaccharide is de-
tected in cell extracts of patient ﬁbroblasts (m/z 540)
(Figure 7A). The small amount of IdoUA-GalNAc4S seen
in digests of the medium from patient ﬁbroblasts probably
reﬂects DS present in the fetal calf serum because there is
no evidence of biosynthetic incorporation of 34S-sulfate
into IdoUA-GalNAc4S disaccharide (m/z 542) from the
medium of patient ﬁbroblasts. In contrast, GlcUA-Gal-
NAc4S is increased in glycosaminoglycans obtained fromJournal of Human Genetics 85, 873–882, December 11, 2009 877
cell extracts and media of patient ﬁbroblasts (m/z 540) and
can be biosynthetically labeled with 34S-sulfate (m/z 542).
Although there is evidence of biosynthetic incorporation
of 34S-sulfate (m/z 537 peak) into CS associated with the
cell pellet, there is no evidence of biosynthetic incorpora-
Figure 5. Consequences of D4ST1 Mutations
(A) Comparative analysis of D4ST1 orthologs and HNK-1 family
members by ClustalWalignment shows a high degree of conserva-
tion of residues mutated in ATCS.
(B) Analysis of epitope-tagged D4ST1 by SDS-PAGE. HEK293/T
cells were transfected with pcDNA3.2/V5 (Invitrogen) expressing
D4ST1 wild-type, p.[R135G; L137Q], p.R213P, pV49X, or
p.Y293C. Cells were washed and dissolved in TPER. Samples
that were or were not treated with N-glycanase prior to separa-
tion by SDS-PAGE are indicated by þ and , respectively. One
percent of the cell extract (upper panel) and 2% and 5% of the
concentrated medium (lower panel) was analyzed for each
construct. The apparent molecular weight standards are indicated
by arrows. Wild-type D4ST1 migrates as a major species with a Mr
of 55 kD and less prominent species with a Mr of 44 kD that
arises by proteolytic cleavage in the region between the trans-
membrane domain and the glycosylated asparagine located at
position 110.878 The American Journal of Human Genetics 85, 873–882, Decembtion of 34S-sulfate (m/z 537 peak) into CS present in the
medium of normal ﬁbroblasts (Figure 7A). This suggests
that DS rather than CS is the predominant proteoglycan
produced by normal ﬁbroblasts. Thus, the overall synthesis
of cell-associated DS and CS glycosaminoglycans is
reduced in patient ﬁbroblasts, whereas the synthesis of
DS and CS glycosaminoglycans that are secreted into the
medium does not appear to be reduced in patient cells, sug-
gesting that diversion of DS into CS is more extensive for
the secreted glycosaminoglycans of patient ﬁbroblasts.
The amount of cell- and of medium-associated nonsulfated
GlcUA-GalNAc and IdoUA-GalNAc disaccharides was
increased for patient ﬁbroblasts as compared to normal
ﬁbroblasts (Figure 7B). Thus, the levels of both GlcUA-Gal-
NAc and IdoUA-GalNAc are increased in the absence of
IdoUA-GalNAc sulfation by D4ST1.
Discussion
ATCS represents a recognizable, generalized connective
tissue disorder with normal cognitive development18–21
and resembles both the progeroid and vascular types of
Ehlers-Danlos syndrome (EDS, [MIM 130070 and 130050])
and the Loeys-Dietz syndrome (LDS [MIM 609192])
because of wasted build and translucent skin. The dynamic
nature of distal contractures in the presence of striking
hypermobility of distal joints is reminiscent of collagen
VI-related muscle disorders (Bethlem myopathy [MIM
158810]) during childhood.27 Characteristic facial features
are shared in part with LDS patients28 and autosomal-
recessive cutis laxa type II, a type II N-glycosylation defect
(ARCL2 [MIM 219200]).29,30 Congenital malformations of
a wide spectrum occur variably in ATCS and include the
unusual coincidence of a common mesentery and absence
of the gastrocolic omentum in a sib pair.
Our data suggest that ATCS is genetically homogeneous
and is caused by loss-of-function mutations in CHST14
leading to a deﬁciency of sulfated dermatan in affected
tissues. Conversion of GlcUA to IdoUA by glucuronate
C5-epimerase is a freely reversible reaction that favors the
Table 1. In Silico Analysis of CHST14 Mutations
Mutation
POLYPHEN
Prediction
POLYPHEN
Score1 
Score2
PANTHER
SubPSEC
PANTHER
Pdeleterious
p.R213P Probably
damaging
2.688 7.74542 0.99138
p.R135G Probably
damaging
2.164 3.19552 0.54872
p.L137Q Possibly
damaging
1.981 2.22168 0.31468
p.Y293C Probably
damaging
2.995 7.76921 0.99158
PolyPhen scores of > 2.0 and PANTHER SubPSEC scores < 3.0 indicate
mutations as probably damaging protein function.er 11, 2009
GlcUA form,6 and our results support the hypothesis that
the addition of sulfate to the C4 hydroxyl of GalNAc by
D4ST1 prevents further epimerization of IdoUA to GlcUA.
ATCS patient ﬁbroblasts epimerize GlcUA-GalNAc to
IdoUA-GalNAc but are not able to add sulfate to the
IdoUA-GalNAc. Our data show that in the absence of
sulfate addition to IdoUA-GalNAc by D4ST1, the levels of
IdoUA-GalNAc, GlcUA-GalNAc, and GlcUA-GalNAc4S
increase, and that a signiﬁcant fraction of DS is, as a result,
replaced by CS. Supposedly, CS cannot generally substitute
for functions specially associated with DS because D4ST1
deﬁciency causes ATCS.
It remains a possibility that D4ST1 loss of function is
incomplete in the patient in whom ﬁbroblasts were
studied. We cannot exclude the possibility that some or
all mutants retain residual enzyme activity or that D4ST1
activity is compensated for in part by C4ST activity at least
in some tissues. Together with the identiﬁcation of an
early-truncating p.V49X mutation in one family with
ATCS, however, our evidence is sufﬁcient to argue for
D4ST1 loss of function as the immediate mechanism of
action to cause the disease. ATCS might result both from
abnormal and from loss of DS proteoglycan function. For
example, osteopenia is present in ATCS patients and in
null mice for biglycan, one of the most intensely studied
DS proteoglycans, suggesting that biglycan’s function as
a positive regulator of bone formation is compromised by
D4ST1 deﬁciency.31,32 The shared features of ATCS and
the progeroid form of EDS might result from a reduction
in the amount of DS proteoglycans. A decrease of glycos-
aminoglycan chains on decorin and biglycan was observed
in ﬁbroblasts from patients with the progeroid form of
EDS. This disease results from reduced activity of Beta4-
GalT7, which catalyzes the transfer of galactose to the
xylose residue forming the linkage region of proteogly-
Figure 6. Light and Electron Microscopy
of a Skin Biopsy from the Austrian ATCS
Patient Homozygous for CHST14 p.R213P
Normal light microscopy (LM) appearance
of the skin using (A) H&E, (B) Elastica, and
(C) PAS staining. (D) EM shows collagen
ﬁbrils, which are normally packed, round,
and have a normal diameter and contour,
as well as normal cross-sections of elastin
ﬁbers and collagen ﬁbrils. Elastin contains
normal microﬁbrillar material.
cans.33 In contrast to the progeroid
form of EDS and to decorin null
mice, however, which have abnor-
mally fragile skin and irregular and
loosely packed collagen skin ﬁbers,34
the patient’s skin appeared thin and
more translucent than normal, but
no ultrastructural skin abnormalities
were apparent in one ATCS patient,
suggesting that an excess of CS might
compensate for DS in the skin, at least postnatally. The
same might hold true for other tissues in which D4ST1 is
expressed.
DS proteoglycans are involved in the generation of
morphogen gradients in epithelia.12,13,35 Because decorin
neutralizes the activity of TGFB1,31 deﬁciency or substitu-
tion of DS chains by CS on decorin implicates altered
TGFB1 signaling in the pathogenesis of ATCS, as was
shown in LDS.28 Altered TGFB1 signaling might lead to
features shared by LDS and ATCS.36 Intriguingly, a homo-
zygous disruption of the C4st1 locus in mice led to a severe
chondrodysplasia and affected the balance of TGFB family
signaling in the cartilage growth plate.37
The single DS chain of decorin binds to tenascin-X (TNX
[MIM 600985]), an ECM protein that binds to tropoelastin
and collagen types I, III, V, XII, and XIV38 and contributes
to the integrity of the extracellular network.39 Loss of
tenascin-X results in a form of EDS with skin and joint
hypermobility and poor wound healing (MIM 606408).40
Decreased TNX binding might be responsible for the
occurrence of features resembling TNX deﬁciency in
ATCS patients.
DS activates heparin cofactor II (HCF2 [MIM 142360])
in the arterial wall after endothelial injury and thereby
exerts an antithrombotic effect, and 4-O-sulfation of DS
is required for this effect.41 DS also shows a localized pro-
ﬁbrinolytic activity.42 D4ST1 deﬁciency would thus be
predicted to cause both thrombophilia and delayed ﬁbri-
nolysis resulting in the observed tendency to ecchymoses
and hematoma formation of patients.
A large number of proteoglycan and of glycosamino-
glycan biosynthetic enzymes have been identiﬁed with
profound effects on growth and morphogenesis by the
study of human disorders and animal models.10,11,43 To
date, these include two sulfotransferases, chondroitinThe American Journal of Human Genetics 85, 873–882, December 11, 2009 879
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Figure 7. Defective Dermatan Sulfation and Increased CS Biosynthesis
Cultured ﬁbroblasts from a patient homozygous for D4ST1 mutation p.R213P detected by 34S-sulfate metabolic labeling and capillary
HPLC/MS analysis of CS-speciﬁc, DS-speciﬁc, and CS and DS-speciﬁc monosulfated (A) and nonsulfated (B) disaccharides.
(A) Monosulfated disaccharides from cell extracts and media of patient (m/z 540) and normal ﬁbroblasts (m/z 535) coeluted at 19 min.
No DS-derived IdoUA-GalNAc4S disaccharide was detected by GRIL capillary HPLC-coupled MS disaccharide analysis of cell extracts
from patient ﬁbroblasts. In addition, GlcUA-GalNAc4S was greatly increased in glycosaminoglycans obtained from cell extracts and
media of patient as compared with control ﬁbroblasts.
(B) Nonsulfated disaccharides from patient (m/z 460) and normal ﬁbroblasts (m/z 455) eluted at 16 min after chondroitinase A, B, and
ABC digestion of their glycosaminoglycans. The amount of GlcUA-GalNAc and IdoUA-GalNAc is increased in the cell extract and the
medium from patient ﬁbroblasts as compared to normal ﬁbroblasts.6-sulfotransferase (CHST3 [MIM 603799]) and N-acetylglu-
cosamine 6-O-sulfotransferase (CHST6 [MIM 605294]),
whose deﬁciencies lead to characteristic human disorders
with symptoms conﬁned to the skeleton and cornea,
respectively, Omani type of spondyloepiphyseal dysplasia
(MIM 608637), recessive Larsen syndrome (MIM
245600),44,45 and macular corneal dystrophies types I
and II (MIM 217800).46 Distinctive diseases can also be
caused by decreased concentrations of intracellular sulfate
and 30-phosphoadenosine 50-phosphosulfate, probably
resulting in broad nonspeciﬁc undersulfation of glycos-
aminoglycan chains as demonstrated in the Pakistani
type of spondyloepimetaphyseal dysplasia (MIM 612847)
and diastrophic dysplasia (MIM 222600), caused by
PAPSS2 (MIM 603005) and SLC26A2 (MIM 606718) deﬁ-
ciencies, respectively. To the best of our knowledge, ATCS
represents the ﬁrst disorder caused by a defect speciﬁc to
DS biosynthesis, and the loss of D4ST1 activity affects a880 The American Journal of Human Genetics 85, 873–882, Decembnumber of tissues. Furthermore, the wide and variable
spectrum of congenital malformations in ATCS patients
implicates roles for DS not only in connective tissue main-
tenance but also in embryonic development, supported by
the recent observation that abrogation of endogenous DS
affects the development of the primary axis, mesoderm
induction, and neuronal differentiation related to FGF
signaling in the Xenopus embryo.35
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